CVR 41951567Public limited company (A/S)Forskning og eksperimentel udvikling inden for naturvidenskab og teknik (721000)HørsholmFounded 17 Dec 2020
Dandex has recorded no changes to this company since it began following the register.
Compiled by Dandex from the Central Business Register (CVR, datacvr.virk.dk), Erhvervsstyrelsen, and annual reports filed in XBRL. Values marked Dandex estimate are computed by Dandex from that data, not registered.
Dandex is Danish company data. Connect it once and ask about Mycometer A/S, or any Danish company, from your assistant, the API or the command line. Answers come from the current record: owners and the ownership network, financials year by year, and the latest registered changes.
Set Up DandexEmployees
17
CVR registry, Aug 2026
+2 (+13.3%) over 12 months
Gross profit
5.9M
DKK, annual report 2025
-30.8% on 2024
Result
-2.9M
DKK, annual report 2025
Equity
9.1M
DKK, annual report 2025
MVA & CO HOLDING ApSCVR 31468841, 25% to under 33.3% of capital and votes, since 17 Dec 2020
OPUS FUNGUS ApSCVR 31468833, 25% to under 33.3% of capital and votes, since 17 Dec 2020
and 2 moreMorten Anders Ulsøe Reeslevsince 17 Dec 2020
CVR 3146884125% to under 33.3% of capital and votessince 17 Dec 2020
CVR 3146883325% to under 33.3% of capital and votesnotified 25 Sep 2024since 17 Dec 2020
CVR 4496857620% to under 25% of capital and votessince 25 Sep 2024
CVR 4497010420% to under 25% of capital and votessince 25 Sep 2024
Holders of 5% or more, from the owner register. CVR records shares in bands, not exact figures.
66.7% to under 90% of capital and votes1 Mar 2024 to 1 Mar 2024
17 Dec 2020 to 5 Nov 2026.
Aug 2026, monthly: 17 employees, 6 FTE
Arrow keys move through the periods, Home and End go to the first and the latest, Escape returns to the latest.
| Period | Jan 2021 | Feb 2021 | Mar 2021 | Apr 2021 | May 2021 | Jun 2021 | Jul 2021 | Aug 2021 | Sep 2021 | Oct 2021 | Nov 2021 | Dec 2021 | Jan 2022 | Feb 2022 | Mar 2022 | Apr 2022 | May 2022 | Jun 2022 | Jul 2022 | Aug 2022 | Sep 2022 | Oct 2022 | Nov 2022 | Dec 2022 | Jan 2023 | Feb 2023 | Mar 2023 | Apr 2023 | May 2023 | Jun 2023 | Jul 2023 | Aug 2023 | Sep 2023 | Oct 2023 | Nov 2023 | Dec 2023 | Jan 2024 | Feb 2024 | Mar 2024 | Apr 2024 | May 2024 | Jun 2024 | Jul 2024 | Aug 2024 | Sep 2024 | Oct 2024 | Nov 2024 | Dec 2024 | Jan 2025 | Feb 2025 | Mar 2025 | Apr 2025 | May 2025 | Jun 2025 | Jul 2025 | Aug 2025 | Sep 2025 | Oct 2025 | Nov 2025 | Dec 2025 | Jan 2026 | Feb 2026 | Mar 2026 | Apr 2026 | May 2026 | Jun 2026 | Jul 2026 | Aug 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Employees | 16 | 17 | 17 | 17 | 17 | 17 | 14 | 13 | 12 | 13 | 14 | 16 | 17 | 18 | 19 | 19 | 17 | 18 | 17 | 16 | 16 | 18 | 18 | 18 | 17 | 16 | 16 | 17 | 16 | 16 | 15 | 16 | 15 | 15 | 16 | 16 | 15 | 15 | 15 | 15 | 11 | 14 | 14 | 15 | 16 | 15 | 15 | 16 | 15 | 15 | 14 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 16 | 17 | 18 | 17 |
| FTE | 6 | 6 | 6 | 7 | 7 | 6 | 6 | 5 | 5 | 6 | 5 | 6 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 6 | 6 | 7 | 7 | 7 | 6 | 6 | 6 | 7 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 7 | 6 | 7 | 7 | 9 | 4 | 7 | 6 | 6 | 7 | 6 | 6 | 7 | 6 | 7 | 7 | 6 | 7 | 7 | 6 | 7 | 7 | 6 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 6 | 7 | 6 |
| Series | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly |
The legal entity's own headcount as CVR records it, not the annual report's average, which may cover a group. Monthly Jan 2021 to Aug 2026.
Latest Aug 2026, published 21 Oct 2026. Source: CVR employment series (Årsbeskæftigelse, Kvartalsbeskæftigelse, Månedsbeskæftigelse).
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Gross profit | 5,341 | 6,440 | 5,923 | 8,526 | 5,902 |
| Operating profit | +1,141 | +1,052 | +259 | +2,998 | 0 |
| Result for the year | +1,398 | +1,020 | -536 | +2,335 | -2,927 |
| Equity | 15,636 | 16,655 | 15,120 | 14,455 | 9,128 |
| Total assets | 19,746 | 19,923 | 18,318 | 17,267 | 11,597 |
| Employees (average) | 6 | 6 | 6 | 6 | 6 |
| Credit metrics (Dandex calculations) | |||||
| Gross profit growth (vækst i bruttofortjeneste) | -5.4% | 20.6% | -8% | 44% | -30.8% |
| EBITDA | 2,725 | 2,650 | 1,810 | 4,538 | 1,546 |
| EBITDA / gross profit (EBITDA i procent af bruttofortjenesten) | 51% | 41.2% | 30.6% | 53.2% | 26.2% |
| Employee growth (vækst i antal ansatte) | 20% | 0% | 0% | 0% | 0% |
| Net interest-bearing debt (NIBD, nettorentebærende gæld) | -2,472note 1 | -3,934note 1 | -5,459note 1 | -5,287note 1 | -2,455note 1 |
| Gearing, NIBD / EBITDA | Net cashnote 1 | Net cashnote 1 | Net cashnote 1 | Net cashnote 1 | Net cashnote 1 |
| ROIC (afkast af investeret kapital) | 7.3%note 1 | 6.3%note 1 | 1.8%note 2 | 24.5%note 1 | 0%note 2 |
| Capex (investeringer i anlægsaktiver) | 180note 3 | 146note 3 | 49note 3 | Not reportednote 4 | 0note 5 |
| NIBD incl. group and owner balances (NIBD inkl. koncern- og ejermellemværender) | -5,594note 1 | -6,443note 1 | -6,681note 1 | -6,667note 1 | -3,348note 1 |
DKK thousands. Annual reports via XBRL. Employees are the annual report's average and may cover a group.
Credit metrics are Dandex calculations from the filed figures, not filed values; estimates are in grey with a note. Ratios are percentages and gearing a multiple. Definitions. Revenue-based rows are empty: the company reports gross profit only (bruttofortjeneste), which class B filers may. No cash flow statement filed (class A and B are exempt).
Annual report 2025
1 Jan 2025 to 31 Dec 2025, published 1 May 2026
Annual report 2024
1 Jan 2024 to 31 Dec 2024, published 4 Jun 2025
Annual report 2023
1 Jan 2023 to 31 Dec 2023, published 24 May 2024
Annual report 2022
1 Jan 2022 to 31 Dec 2022, published 27 Apr 2023
Annual report 2021
1 Jan 2021 to 31 Dec 2021, published 11 Apr 2022
Each registered value from the day it took effect, newest first.
Demerger (Spaltning), as the receiving company (Modtagende selskab)
From CVR, read 5 Nov 2026. Text such as the signing rule and purpose is shown as registered.
1 registration, newest first. As published by Erhvervsstyrelsen, in Danish, with people's street addresses cut to postcode and city.
Erhvervsstyrelsen har modtaget oplysning om, at der er truffet beslutning om nedenstående spaltning.
Virksomheden er d. 17.12.2020 opstået efter spaltning. Aktiver og gæld er overdraget fra CVR-nummer: 24231712 BactiQuant A/S.
Seneste vedtægtsdato: 17.12.2020.
Kapital:
kr. 400.000,00.
Kapitalklasser: Nej
Indbetalingsmåde: Indbetalt ved spaltning kr. 400.000,00 til kurs 4.077,52, fuldt indbetalt.
Bestyrelse:
Henrik Skaanderup, (formand), den 17.12.2020, Jens Lassen, den 17.12.2020, Morten Anders Ulsøe Reeslev, den 17.12.2020.
Direktion:
Morten Anders Ulsøe Reeslev, den 17.12.2020.
Selskabet tegnes af én direktør eller af den samlede bestyrelse.
Revision:
CVR-NR. 25160037 PIASTER REVISORERNE, STATSAUTORISERET REVISIONSAKTIESELSKAB, Engholm Parkvej 8, 3450 Allerød, den 17.12.2020.
Første regnskabsår:
01.01.2020 - 31.12.2020.
Regnskabsår:
01.01 - 31.12.
Formål:
Selskabets formål er at drive virksomhed med fremstilling og salg af mikrobiologiske metoder til måling af mikrobiel kontaminering, og dermed beslægtet virksomhed.
1 registered in CVR.
P-number 1026595823Dr Neergaards Vej 3, 2970 Hørsholm
